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Magnesium abnormalities are common in patients with
congestive heart failure but the clinical and prognostic
significance of an abnormal serum magnesium concentra-
tion in this disorder has not been investigated. Therefore,
the relation between serum magnesium concentration and
the clinical characteristics and long-term outcome of 199
patients with chronic heart failure was evaluated. The
serum magnesium concentration was <1.6 mEq/liter in 38
patients (19%), within the normal range in 134 patients
(67%) and >2.1 mEqlIiter in 27 patients (14%).
Patients with hypomagnesemia had more frequent ven-
tricular premature complexes and episodes of ventricular
tachycardia than did patients with a normal serum magne-
sium concentration (p < 0.05). Even though the two groups
were similar with respect to severity of heart failure and
Patients with congestive heart failure characteristically man-
ifest a variety of electrolyte abnormalities that are related to
both the pathophysiology and the treatment of the disorder.
These patients may have hypokalemia (1,2) (secondary to
activation of the renin-angiotensin system or the use of
diuretic drugs) or hyperkalemia (2,3) (secondary to the
development of renal insufficiency or the use of angiotensin-
converting enzyme inhibitors). Patients with heart failure
may also exhibit hyponatremia, which may be related to the
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neurohormonal variables, patients with a low serum mag-
nesium concentration had a significantly worse prognosis
during long-term follow-up (45% versus 71 % 1 year sur-
vival, p < 0.05). Patients with hypermagnesemia had more
severe symptoms, greater neurohormonal activation and
worse renal function than did patients with a normal serum
magnesium concentration but tended to have fewer ventric-
ular arrhythmias. Hypermagnesemic patients had a worse
prognosis than did those with a normal magnesium concen-
tration (37% versus 71 % 1 year survival, p < 0.05).
In conclusion, the measurement of serum magnesium
concentration provides important clinical and prognostic
information in patients with chronic heart failure.
(J Am Coli CardiolI990;I6:827-3I)
enhanced release of both angiotensin and vasopressin and
can be exacerbated by diuretic therapy (4). Such altered
concentrations of potassium and sodium have important
clinical and prognostic significance. Hypokalemia and hy-
perkalemia may increase the risk of sudden death by their
effects on cardiac excitability and conduction (2,5) and
hyponatremia has been associated with an increased risk of
death from progressive heart failure (4), bradyarrhythmias
and electromechanical dissociation (6).
Many of the factors that interact to alter the concentra-
tion of sodium and potassium in patients with heart failure
may also disturb magnesium homeostasis in this disorder.
Digoxin, diuretics and activation of the renin-angiotensin
system may increase the renal excretion of magnesium and
lead to hypomagnesemia (7), whereas poor renal function
may impair the excretion of this cation and lead to hyper-
magnesemia (8). Despite the prevalence of these factors, the
clinical significance of hypomagnesemia and hypermag-
nesemia in heart failure has not been evaluated; even the
prevalence of an abnormal serum magnesium concentration
in this disorder remains controversial (9-11). To address
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these questions, we investigated both the prevalence and
clinical importance of an abnormal serum magnesium con-
centration in a large group of patients with chronic heart
failure.
Methods
Study patients. Our study group consisted of 199 patients
with chronic congestive heart failure referred for treatment
with vasodilator or inotropic drugs. There were 144 men and
55 women aged 28 to 90 years (mean 64). The cause of heart
failure was ischemic heart disease in 102 patients, dilated
cardiomyopathy in 88 and primary mitral or aortic valvular
insufficiency, or both, in 9 patients. The left ventricular
ejection fraction by radionuclide ventriculography ranged
from 2% to 39% (mean 19%). Thirty-seven patients were in
New York Heart Association functional class II, 77 patients
were in class III and 85 patients were in class IV but all were
clinically stable at the time of evaluation. All patients were
receiving constant doses of digoxin and diuretics and none
had received any vasodilator or antiarrhythmic medications
within 5 days.
Patient characterization. After an indwelling intravenous
line was inserted, patients were permitted to rest for 30 min
in a quiet room. After this equilibration period, blood was
collected for the following measurements: I) serum magne-
sium, potassium, sodium, creatinine and blood urea nitrogen
(199 patients); 2) plasma norepinephrine by radioenzymatic
assay (114 patients); and 3) plasma renin activity (146
patients), aldosterone (99 patients) and arginine vasopressin
(89 patients) by radioimmunoassay.
Twenty-four hour ambulatory electrocardiographic
(ECG) recordings were obtained in 106 patients within 7
days of these hormonal and electrolyte measurements and
were scanned for the presence of ventricular premature
complexes and ventricular tachycardia. Ventricular tachy-
cardia was defined as three or more consecutive ventricular
complexes at a rate of at least 100 beats/min.
Data analysis. Patients were divided into three groups
based on their serum magnesium concentration (low, normal
or high); a normal serum magnesium level was defined as a
concentration between 1.6 and 2.1 mEq/liter, range of values
obtained in 90% of control subjects. Qualitative and quanti-
tative differences among the three subgroups were tested for
significance with use of the chi-square statistic and analysis
of variance, respectively.
Long-term survival was assessed from the day of magne-
sium determination to the day of death or to June I. 1988.
Death was classified as sudden if unexpected circulatory
collapse occurred in a clinically stable patient (12); this
assessment was made without knowledge of the patient's
serum magnesium concentration. Patients were considered
lost to follow-up if the long-term clinical outcome was
unknown (eight patients, survival censored after date of last
visit) or if cardiac transplantation occurred (one patient,
survival censored after date of transplantation). Cumulative
survival curves for the three magnesium groups were con-
structed by Kaplan-Meier survivorship methods (13) and the
differences between the survival curves were tested for
significance by both Mantel-Cox log rank and Wilcoxon-
Breslow methods (14.15),
Results
The serum magnesium concentration in the 199 patients
ranged from 1.0 to 3.6 mEqlliter (mean 1.8 ± OJ mEq/liter).
The magnesium concentration was >2.1 mEq/liter in 27
patients (14%). within the normal range in 134 patients (67%)
and <1.6 mEq/liter in 38 patients (19%).
Hypomagnesemia. The 38 patients with a serum magne-
sium concentration <1.6 mEq/liter were similar to those
with a normal concentration with respect to age, gender,
cause of heart failure. functional class and neurohormonal
variables (Table I). Hypomagnesemic patients, however,
had more frequent ventricular premature complexes and
episodes of ventricular tachycardia and had a higher serum
creatinine concentration than did patients with a normal
magnesium level (Fig. I). These factors may explain why
patients with a low serum magnesium concentration had a
significantly worse survival rate than did patients with a normal
level (I and 2 year survival of 45% and 42% compared with
71% and 61%. respectively, p < 0.05) (Fig. 2).
Hypermagnesemia. In contrast to the clinical similarity of
the low and normal magnesium groups. the 27 patients with
a serum magnesium concentration >2.1 mEq/liter demon-
strated clinical and biochemical evidence of more severe
heart failure than the normal magnesium group (Table I).
Despite similar values for left ventricular ejection fraction.
patients with a high magnesium concentration were older
and had more severe symptoms, higher circulating levels of
neurohormones and worse renal function than did patients
with a normal serum magnesium. Despite their more ad-
vanced heart failure. patients with a high magnesium con-
centration tended to have a reduced (rather than increased)
frequency of premature ventricular complexes and episodes
of ventricular tachycardia compared with that in patients
who had a normal magnesium concentration (Fig. I). Nev-
ertheless, patients in the high magnesium group had a signifi-
cantly worse prognosis than did those in the normal magnesium
group (I and 2 year survival of 37% and 30% compared with
71% and 61%, respectively, p < 0.05) (Fig. 2).
Cause of death. Of the 93 cardiac deaths in this study, 25
were classified as sudden and unexpected, including 37% of
the deaths that occurred in patients with a low serum
magnesium concentration. 29% of the deaths in patients with
a normal concentration and 17% of the deaths in patients
with a high concentration.
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Table 1. Characteristics of 199 Patients With Chronic Heart Failure Grouped According to Serum
Magnesium Levels
<1.6 mEq/liter 1.6-2.1 mEq/liter >2.1 mEq/liter
Age (yr) 62 ± 2 63 ± I 71 ± 2*
Gender
Men 26 98 20
Women 12 36 7
Etiology
Ischemic 18 67 17
Primary 18 62 8
Valvular 2 5 2
NYHA functional class
II 3 34 0
III 18 52 7
IV 17 48 20*
Ejection fraction ('7t) 19 ± 2 19 ± 1 19 ± 2
Serum potassium (mEq/literl 3.8 ± 0.2 4.2 ± 0.1 3.7 ± OJ
Serum creatinine (mg/dl) 2.1 ± OJ* 1.6±0.1 2.5 ± 0.2*
Serum blood urea nitrogen (mg/dl) 41 ± 6 33 ± 2 67 ± 7*
Plasma renin activity (ng/ml per h) 5.6 ± 1.3 5.0 ± 1.0 11.0 ± 2.8*
Plasma aldosterone (ng/dl) 20 ± 6 30 ± 6 46 ± 16
Plasma norepinephrine (pg/ml) 706 ± 151 653 ± % 966 ± 166
Plasma arginine vasopressin (pg/mll 4 ± I 5 ± I 13 ± 3*
Furosemide dose (mg/day) 95 ± II 82 ± 6 103 ± II
*Statistical significance (p < 0.05) as compared with values in the patients with a normal serum magnesium
concentration. Group data are mean values ± SEM. NYHA = New York Heart Association.
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Figure 2, Actuarial survival rate of patients with a serum magne-
sium (Mg) concentration < 1.6 (n := 38), 1.6 to 2.1 (n := 134) and >2.1
mEq/liter (n := 27). Patients with a normal magnesium concentration
had a more favorable prognosis than that of patients with a low or
high serum level (both p < 0.05).
prognosis that appeared to be related to specific ECG and
metabolic abnormalities. Previous investigations of the po-
tential role of magnesium in heart failure simply defined the
prevalence of an abnormal magnesium value; they did not
attempt to show that an abnormality was associated with
particular clinical characteristics or future events. In the
absence of such information, it was possible that the finding
of a serum magnesium concentration outside the normal
range had only statistical, not biologic, significance. This
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Discussion
This study is the first report to demonstrate the clinical
significance of an abnormal serum magnesium concentration
in patients with chronic heart failure. Compared with pa-
tients whose values fell within the normal range, patients
with hypo- and hypermagnesemia had a significantly worse
Figure 1. Frequency of ventricular premature complexes and epi-
sodes of ventricular tachycardia in 199 patients with a serum
magnesium (Mg) concentration <1.6 (n := 38), 1.6 to 2.1 (n := 134)
and >2.1 mEq/liter (n := 27). An asterisk indicates a statistically
significant difference (p < 0.05) as compared with values in patients
with a normal serum magnesium concentration.
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study indicates that abnormalities of the serum magnesium
concentration are not merely laboratory curiosities but have
important clinical implications.
Patients with hypomagnesemia. Previous investigators
have reported a prevalence of hypomagnesemia varying
from 7% of patients admitted to a coronary care unit with
acute heart failure (11) to 37% of diuretic-treated patients
with chronic cardiac decompensation (10). The present
study confirms the high prevalence of hypomagnesemia in
patients with heart failure (nearly 20%) but fails to elucidate
the mechanisms responsible for this electrolyte abnormality.
Although treatment with digitalis and diuretics and high
circulating levels of aldosterone and vasopressin can in-
crease the urinary excretion of magnesium (7), these factors
did not differ between the low and normal magnesium
groups.
Our data strongly support the conclusion that, regardless
of its cause, the low serum magnesium concentration noted
in many patients with chronic heart failure has clinical
significance; patients with hypomagnesemia had a worse
prognosis than did patients with a normal concentration.
This finding has two possible explanations. First, the low
magnesium concentration may be simply a marker of more
advanced disease; hypomagnesemic patients could have
been more severely ill than patients with a normal concen-
tration. However, the two groups did not differ with respect
to any of the hemodynamic or neurohormonal variables that
we measured. Second, the low magnesium concentration
may have had direct pathogenetic significance. Magnesium
depletion can impair cardiac performance either by reducing
cardiac contractility (16) or by causing peripheral vasocon-
striction (17). However, hypomagnesemic patients in our
study did not show evidence of worse ventricular function.
Instead, their poor prognosis appeared to be related to their
more frequent and complex ventricular arrhythmias because
these patients had a higher prevalence of sudden death than
did the other two magnesium groups. Previous studies
support the concept that magnesium depletion may increase
the frequency of ventricular arrhythmias. A low magnesium
concentration enhances the development of arrhythmias in
the laboratory (18) and clinical setting (19) and the adminis-
tration of magnesium suppresses electrophysiologic abnor-
malities in dogs (20) and in patients (21,22). These actions of
magnesium may be related to its function as a critical
cofactor in the cellular activities that regulate intracellular
electrolyte concentrations (23).
Patients with hypermagnesemia. This study is the first to
identify the presence of an elevated serum magnesium
concentration in a substantial number of patients with
chronic heart failure; nearly one of seven patients had a
serum magnesium level >2.1 mEq/liter. The most common
cause of hypermagnesemia in general medicine is chronic
renal insufficiency (8) presumably because the kidneys pro-
vide the most important route of excretion for magnesium.
Impaired renal clearance of magnesium may therefore ex-
plain the high magnesium concentrations observed in our
patients with chronic heart failure; patients with a high
serum concentration of magnesium had worse renal function
than did patients with a normal serum concentration. The
renal insufficiency in these patients is probably related to
their more advanced age and severity of heart failure, both of
which decrease glomerular filtration (24).
As in the case of hypomagnesemia, the high serum
magnesium concentration seen in some patients with chronic
heart failure was associated with a poor long-term prognosis.
However, this unfavorable outlook did not appear to be a
direct effect of the electrolyte abnormality but may have
been related to the high prevalence of several adverse
prognostic factors in these patients. Patients with a high
serum magnesium concentration were older, had more se-
vere symptoms of heart failure, had worse renal function and
had higher levels of plasma renin activity than did patients
with a normal serum magnesium concentration. All of these
factors have been shown to adversely modify the long-term
outcome of patients with chronic heart failure (25-27). Only
two variables reflecting the severity of heart failure-left
ventricular ejection fraction and ventricular arrhythmias-
were not worse in hypermagnesemic patients than in the
normal magnesium group. The similarity of values for ejec-
tion fraction is not unexpected because the left ventricular
ejection fraction loses its prognostic significance in patients
with advanced heart failure as neurohormonal (rather than
hemodynamic) factors emerge as the primary determinants
of mortality (28). On the other hand, we would have ex-
pected patients with more advanced disease to have more
frequent ventricular arrhythmias (29) but our patients with
hypermagnesemia were least likely to have complex arrhyth-
mias and experience sudden death. These observations
suggest that high levels of magnesium may be associated
with clinically important antiarrhythmic effects.
Limitations. The present study needs to be interpreted
cautiously. Although our findings demonstrate the clinical
importance of serum magnesium measurements in patients
with chronic heart failure, serum levels of magnesium relate
poorly to the levels of magnesium measured in skeletal
muscle, myocardium, lymphocytes or erythrocytes. Tissue
magnesium depletion is common even in patients with a
normal serum magnesium concentration and, conversely,
hypomagnesemia may coexist with normal tissue levels of
the cation (30,31). However. the clinical relevance of tissue
levels of magnesium is not known. It is possible that serum
levels may be as important (if not more important) as tissue
levels in determining the arrhythmogenic potential of mag-
nesium depletion; rapid changes in serum magnesium level
produce significant electrophysiologic effects (32). Future
investigations are needed to determine whether cellular or
serum levels of magnesium are the more important determi-
nant of the cation's electrophysiologic actions.
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Conclusions. The findings of the present study indicate
that patients with chronic heart failure frequently have
clinically important abnormalities of the serum magnesium
concentration. Patients with hypomagnesemia have a poor
prognosis that is probably related to a high prevalence of
ventricular arrhythmias and an increased risk of sudden
death. In contrast, hypermagnesemic patients have a poor
prognosis that is related to the severity of disease, poor end
organ function and neurohormonal activation. Further work
is needed to determine whether efforts to change the serum
magnesium concentration can modify the prognosis of these
severely ill patients.
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